7 Matching Annotations
  1. Last 7 days
    1. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors

      [Paper-level Aggregated] PMCID: PMC4411002

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The presence of PIK3CA mutations, specifically c.241 G>A [p.E81K], c.3140 A>G [p.H1047R], and c.3140 A>T [p.H1047L], in patients with a clinical diagnosis of FAO suggests a role in tumorigenesis, as these mutations are associated with cancer-related pathways. Functional: The identification of specific mutations in PIK3CA and their varying frequencies in different tissue types indicates that these mutations may affect the function of the protein, contributing to the disease phenotype observed in the patients.

      Gene→Variant (gene-first): PIK3CG(5294):3140 A>T PIK3CA(5290):c.3140 A>G PIK3CA(5290):c.3140 A>T PIK3CA(5290):p.H1047L PIK3CA(5290):p.H1047R PIK3CA(5290):c.241 G>A PIK3CA(5290):p.E81K

      Genes: PIK3CG(5294) PIK3CA(5290)

      Variants: 3140 A>T c.3140 A>G c.3140 A>T p.H1047L p.H1047R c.241 G>A p.E81K

    2. In both patients with a clinical diagnosis of FAO (patients 2 and 3), targeted deep sequencing analysis led to the identification of a PIK3CA mutation in primary fibroblasts samples only. Specifically, a c.3140 A>G [p.H1

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 16

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of PIK3CA mutations in patients with a clinical diagnosis of FAO, indicating that these variants are used to define or confirm the disease in these patients. Oncogenic: The PIK3CA mutations mentioned are somatic variants identified in primary fibroblasts, which suggests they contribute to tumor development or progression in the context of the patients' disease.

      Gene→Variant (gene-first): 5294:3140 A>T 5290:c.3140 A>G 5290:c.3140 A>T 5290:p.H1047L 5290:p.H1047R

      Genes: 5294 5290

      Variants: 3140 A>T c.3140 A>G c.3140 A>T p.H1047L p.H1047R

    3. This approach confirmed the presence of the c.241 G>A [p.E81K] mutation in the right and left leg biopsies of patient 1, with mutant allele frequencies of 9% and 21.5%, respectively (Fig 1d).

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 15

      Evidence Type(s): Diagnostic

      Justification: Diagnostic: The passage confirms the presence of the c.241 G>A [p.E81K] mutation in the biopsies of a patient, indicating its role in defining or confirming the disease in that individual.

      Gene→Variant (gene-first): 5290:c.241 G>A 5290:p.E81K

      Genes: 5290

      Variants: c.241 G>A p.E81K

    4. Mutational analysis of PIK3CA exons and adjacent intronic regions was performed by Sanger sequencing methods on genomic DNA isolated from blood samples, tissue biopsies, and cultured dermal fibroblasts. No pathogenic var

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of the c.241 G>A [p.E81K] mutation in a specific patient, indicating its association with the patient's condition and its absence in the patient's parents, which suggests its role in defining or confirming a disease. Oncogenic: The mention of the mutation being detected in various tissues of the patient, particularly in the context of a mutational analysis, implies its potential contribution to tumor development or progression.

      Gene→Variant (gene-first): 5290:c.241 G>A 5290:p.E81K

      Genes: 5290

      Variants: c.241 G>A p.E81K

    5. In both patients with a clinical diagnosis of FAO (patients 2 and 3), targeted deep sequencing analysis led to the identification of a PIK3CA mutation in primary fibroblasts samples only. Specifically, a c.3140 A>G [p.H1

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 16

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of PIK3CA mutations in patients with a clinical diagnosis of FAO, indicating that these variants are used to define or confirm the disease in these patients. Oncogenic: The PIK3CA mutations mentioned are somatic variants identified in primary fibroblasts, which suggests they contribute to tumor development or progression in the context of the patients' disease.

      Gene→Variant (gene-first): 5294:3140 A>T 5290:c.3140 A>G 5290:c.3140 A>T 5290:p.H1047L 5290:p.H1047R

      Genes: 5294 5290

      Variants: 3140 A>T c.3140 A>G c.3140 A>T p.H1047L p.H1047R

    6. This approach confirmed the presence of the c.241 G>A [p.E81K] mutation in the right and left leg biopsies of patient 1, with mutant allele frequencies of 9% and 21.5%, respectively (Fig 1d).

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 15

      Evidence Type(s): Diagnostic

      Justification: Diagnostic: The passage confirms the presence of the c.241 G>A [p.E81K] mutation in the biopsies of a patient, indicating its role in defining or confirming the disease in that individual.

      Gene→Variant (gene-first): 5290:c.241 G>A 5290:p.E81K

      Genes: 5290

      Variants: c.241 G>A p.E81K

    7. Mutational analysis of PIK3CA exons and adjacent intronic regions was performed by Sanger sequencing methods on genomic DNA isolated from blood samples, tissue biopsies, and cultured dermal fibroblasts. No pathogenic var

      [Paragraph-level] PMCID: PMC4411002 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of the c.241 G>A [p.E81K] mutation in a specific patient, indicating its association with the patient's condition and its absence in the patient's parents, which suggests its role in defining or confirming a disease. Oncogenic: The mention of the mutation being detected in various tissues of the patient, particularly in the context of a mutational analysis, implies its potential contribution to tumor development or progression.

      Gene→Variant (gene-first): 5290:c.241 G>A 5290:p.E81K

      Genes: 5290

      Variants: c.241 G>A p.E81K